RxDoctor Payments Data

Lakshmi Arekapudi, MD

Internal Medicine · Bay City, MINPI 1053385682

Payments from drug & device makers

$5,816in general payments, 2019–2025

Across 339 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$438
  • GSK$373
  • Merck$334
  • Lilly USA, LLC$285
  • Novartis$276
  • Amgen$268
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$5,791100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,816 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$228,518
Medicare patients
508
Services billed
2,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban459$242,789
MounjaroTirzepatide115$165,999
Trelegy ElliptaFluticasone/Umeclidin/Vilanter132$102,714
HumiraAdalimumab11$73,359
TrulicityDulaglutide40$59,521
JardianceEmpagliflozin66$48,363
XareltoRivaroxaban43$35,087
JanuviaSitagliptin Phosphate25$27,430
EntrestoSacubitril/Valsartan47$20,879
InvokanaCanagliflozin12$19,367
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$18,748
NuedextaDextromethorphan Hbr/Quinidine28$18,331
TrintellixVortioxetine Hydrobromide56$17,459
OzempicSemaglutide12$16,931
LinzessLinaclotide28$16,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$177$242,789459 claims
Lilly USA, LLCMounjaro, Trulicity$285$225,520155 claims
GSKTrelegy Ellipta, Breo Ellipta$373$115,612162 claims
AbbVieHumira, Linzess$181$89,54239 claims
Johnson & JohnsonXarelto, Invokana$264$54,45455 claims
Boehringer IngelheimJardiance$122$48,36366 claims
MerckJanuvia$334$27,43025 claims
NovartisEntresto$276$20,87947 claims
Avanir Pharmaceuticals, Inc.Nuedexta$68$18,33128 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$117$17,45956 claims
Novo NordiskOzempic$228$16,93112 claims
AstraZenecaFarxiga$157$13,79816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Bay City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →